6th Annual
November 9-10, 2016  |  Hilton Penn's Landing  |  Philadelphia, PA

The new managed markets paradigm: where should pharma sit?

The results are in – 100s of market access execs told us about their predictions for and frustrations with the development of managed markets in the US.

Here’s a taster of some of the more surprising results:

  • 48% said market access considerations still aren’t being considered till phase 2 of drug development
  • The shift towards specialty medicines no longer seems to be seen as a challenge
  • But clarity from payers is still the Holy Grail for market access execs

Download the results in full on the right 

I look forward to hearing your thoughts!



Aidan Brain

VP Market Access

+44 (0)207 375 7513